Previously, we have shown that orally administered topiramate, a sulfamate-substituted fructopyranose derivative, appears to accentuate rather than diminish some aspects of methamphetamine-induced positive subjective mood and cognitive performance. One possible mechanism by which this might occur would be for topiramate to increase plasma methamphetamine level. Such an effect also would be expected to enhance methamphetamine-induced hemodynamic response. We, therefore, studied -in the same experiment from which the previous findings originated -the effects of topiramate on the kinetic profile and hemodynamic response to methamphetamine. In a 27-day inpatient study, 10 methamphetamine-dependent individuals participated in a double-blind, placebo-controlled, cross-over design, with oral doses of topiramate (0, 100, and 200 mg) administered as a pretreatment before intravenous doses of methamphetamine (0, 15, and 30 mg). The 3 × 3 factorial combination of topiramate and methamphetamine resulted in a sequence of the nine treatments administered to each subject in an order determined by a 9 × 9 Latin Square design. Methamphetamine alone was associated with prototypical increases in hemodynamic response that were not altered in the presence of topiramate. While there was no significant kinetic interaction between topiramate and methamphetamine, there was a nonsignificant trend for topiramate to increase plasma methamphetamine level. No significant adverse events were reported. The combination of topiramate and methamphetamine at pharmacologically relevant doses appears to be safe. Larger laboratory studies with chronic dosing regimens are needed to establish whether or not there is a kinetic interaction between topiramate and methamphetamine.
Introduction
Previously, we have shown that topiramate, a sulfamatesubstituted fructopyranose derivative, appears to accentuate some aspects of methamphetamine-induced positive subjective mood (Johnson et al., in press-a) and cognitive performance (Johnson et al., in press-b). Topiramate's enhancement of methamphetamine's positive subjective effects was the converse of the expected findings. While topiramate's primary pharmacological effects -facilitation of gamma-aminobutyric acid (GABA) and inhibition of kainate and alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid-type glutamate pathways -should decrease cortico-mesolimbic dopamine activity (Johnson, 2005; Schiffer et al., 2001) , leading us to hypothesize that topiramate would decrease positive subjective mood, topiramate enhanced it instead. Also, topiramate's antiglutaminergic effect was expected to antagonize methamphetamine-induced increases in accuracy of responding in a sequential attentional task; instead, topiramate improved it.
